Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CYTOMX THERAPEUTICS, INC.

(CTMX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
6.52(c) 6.61(c) 6.7(c) 6.9(c) 6.61 Last
1 024 821 2 295 202 1 168 250 876 142 828 299 Volume
-3.41% +1.38% +1.36% +2.99% -4.20% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 68,7 M - -
Net income 2021 -71,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,92x
Yield 2021 -
Sales 2022 83,0 M - -
Net income 2022 -101 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,60x
Yield 2022 -
Capitalization 431 M 431 M -
Capi. / Sales 2021 6,27x
Capi. / Sales 2022 5,20x
Nbr of Employees 145
Free-Float 98,6%
More Financials
Company
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in... 
More about the company
Ratings of CytomX Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about CYTOMX THERAPEUTICS, INC.
11/15BTIG Starts CytomX Therapeutics at Buy With $16 Price Target
MT
11/11CytomX Therapeutics to Present at Upcoming November Investor Conferences
GL
11/04CYTOMX THERAPEUTICS : Q3 Earnings Snapshot
AQ
11/04CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Busines..
PU
11/04CytomX Therapeutics Announces Third Quarter 2021 Financial Resultsáand Provides Busines..
GL
11/04CYTOMX THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
11/04CytomX Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
11/01CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Pl..
AQ
11/01CytomX Therapeutics, Inc. to Present Preclinical Data for Conditionally Activated Cytok..
CI
10/28CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 202..
AQ
10/18CYTOMX THERAPEUTICS : Announces New Employment Inducement Grants
AQ
10/04CYTOMX THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/04CYTOMX THERAPEUTICS : Appoints Dr. Alan Ashworth to Board of Directors
GL
10/04Cytomx Therapeutics, Inc. Appoints Alan Ashworth to Board of Directors
CI
09/16CYTOMX THERAPEUTICS : Announces New Employment Inducement Grants
AQ
More news
News in other languages on CYTOMX THERAPEUTICS, INC.
08/05Earnings Flash (CTMX) CYTOMX THERAPEUTICS affiche un chiffre d'affaires de 16 millions ..
05/28RAPPORT DE LA MI-JOURNÉE : Wall Bourse en hausse à la mi-journée, ignorant le pic de la ja..
More news
Analyst Recommendations on CYTOMX THERAPEUTICS, INC.
More recommendations
Chart CYTOMX THERAPEUTICS, INC.
Duration : Period :
CytomX Therapeutics, Inc. Technical Analysis Chart | CTMX | US23284F1057 | MarketScreener
Technical analysis trends CYTOMX THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 6,61 $
Average target price 12,86 $
Spread / Average Target 94,5%
EPS Revisions
Managers and Directors
Sean A. McCarthy Chairman, President & Chief Executive Officer
Carlos E. Campoy Chief Financial Officer & Senior Vice President
Alison L. Hannah Chief Medical Officer & Senior Vice President
Marcia P. Belvin Senior Vice President & Head-Research
Danielle Olander Senior VP-Talent & Systems Development
Sector and Competitors
1st jan.Capi. (M$)
CYTOMX THERAPEUTICS, INC.5.34%450
GILEAD SCIENCES, INC.19.58%87 393
BIONTECH SE310.30%80 545
REGENERON PHARMACEUTICALS31.23%66 288
WUXI APPTEC CO., LTD.26.31%65 499
VERTEX PHARMACEUTICALS-13.49%51 982